Potential clinical use of azithromycin against gastroenteritis-causing pathogens other than Campylobacter Casanovas-Moreno-Torres, Isabel Gutiérrez-Soto, Blanca Diana Modovan, Teodora Expósito Ruiz, Manuela Navarro-Marí, José María Gutiérrez Fernández, José The activity of azithromycin against enteritis-producing agents other than Campylobacter spp. was studied. The susceptibility to azithromycin, through gradient test, of 88 clinical isolates (51 Salmonella spp., 23 Aeromonas spp., 10 Shigella sonnei and 4 Yersinia enterocolitica) for one year was studied prospectively. The results were compared with the activity of ampicillin, trimethoprim-sulfamethoxazole and ciprofloxacin by microdilution. For azithromycin, the minimum inhibitory concentration (MIC) 50 and MIC90 were 4 and 12 mg/l, respectively. Six (6.8%) isolates were simultaneously resistant to ampicillin, trimethoprim- sulfamethoxazole and ciprofloxacin, and 3 (50%) of them presented a MIC >256 mg/l. Azithromycin may be a good empirical therapeutic option for the treatment of bacterial enteritis. 2024-05-08T07:43:13Z 2024-05-08T07:43:13Z 2020-10 info:eu-repo/semantics/article Casanovas-Moreno-Torres I, Gutiérrez-Soto B, Modovan TD, Expósito-Ruiz M, Navarro-Marí JM, Gutiérrez-Fernández J. Potential clinical use of azithromycin against gastroenteritis-causing pathogens other than Campylobacter. New Microbiol. 2020 Oct;43(4):198-200 PMID: 33021318 https://hdl.handle.net/10481/91518 eng http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess Attribution-NonCommercial-NoDerivatives 4.0 Internacional New Microbiol